Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 18Neoplasm Metastasis 6Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Breast Cancer Female 1Advanced Breast Cancer 1

Interventions

Carboplatin 190Cisplatin 156Pemetrexed 151Paclitaxel 127Docetaxel 109pembrolizumab 87Gemcitabine 73Erlotinib Hydrochloride 44Radiotherapy 39Vinorelbine 35Gefitinib 34durvalumab 31Bevacizumab 28Nivolumab 26Drug Therapy 23atezolizumab 22osimertinib 19130-nm albumin-bound paclitaxel 19tislelizumab 16Crizotinib 16Radiosurgery 15Etoposide 14Surgical Procedures, Operative 11Afatinib 11Ipilimumab 10icotinib 9aumolertinib 9Albumin-Bound Paclitaxel 9Specimen Handling 8Observation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Non-Small-Cell Lung × abemaciclib × Clear all
NCT02152631 2026-02-06

JUNIPER

Eli Lilly and Company

Phase 3 Active not recruiting
453 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡